Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11181948 | 0.81 | TLR4 (0.47) | TLR4ESR2ALDH1A1MAPT | |
| SCHEMBL5201714 | 0.79 | TLR4 (0.55) | TLR4ESR2MAPT | |
| SCHEMBL10975419 | 0.78 | — | — | |
| SCHEMBL9609547 | 0.75 | TLR4 (0.50) | TLR4ALDH1A1MAPT | |
| SCHEMBL15380945 | 0.74 | TLR4 (0.42) | TLR4ESR2MAPT | |
| SCHEMBL20394577 | 0.73 | MAPT (0.45) | TLR4ESR2ALDH1A1MAPT | |
| SCHEMBL1867176 | 0.72 | — | — | |
| SCHEMBL7644421 | 0.71 | TLR4 (0.50) | TLR4ALDH1A1MAPT | |
| SCHEMBL14401277 | 0.70 | TLR4 (0.50) | TLR4ALDH1A1MAPT | |
| SCHEMBL1021749 | 0.70 | TLR4 (0.53) | TLR4ESR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHAMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | NEREUS PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103328-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | TNF, TNFRSF1A, IL1R1 | TLR4 1104/4885ESR2 528/4885ALDH1A1 520/4885 |
| US-20080188475-A1 | Novel Interleukin-1 and Tumor Necrosis Factor-Alpha Modulators, Syntheses of Said Modulators and Their Enantiomers and Methods of Using Said Modulators | IL1A, IL1B, TNF | TLR4 504/4885ESR2 1049/4885ALDH1A1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.